Compare GSK plc (GSK) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Symbotic Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Symbotic Inc trades at $41.19 (market cap $5.41B). The key difference: GSK plc is far larger — about 19× Symbotic Inc's market cap, and GSK plc pays a 3.57% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| GSK | SYM | |
|---|---|---|
Market Cap | $102.60B | $5.41B |
Sector | Health | Technology |
52-Week High | $61.18 | $87.30 |
52-Week Low | $38.22 | $38.57 |
Enterprise Value | $123.04B | $3.67B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
SYM trades at $41.19, up 2.69% with bearish technical signals despite recent earnings misses. The company shows revenue growth potential with 2026 projections of $2.6B revenue and positive net income, but current profitability remains weak with negative EBITDA and slim 0.31% net margin. Recent Q3 2026 earnings missed expectations despite 21.7% revenue growth, causing a 10.3% stock drop according to Defense World on August 7, 2026.
Analyst consensus remains bullish with a $60 price target (61.11% buy ratings), but execution risks persist amid margin pressure and competitive threats. The stock faces near-term headwinds from consecutive earnings misses while long-term robotics automation trends provide growth catalysts. Current valuation metrics show elevated P/E of 1,042.25 and EV/EBITDA of 73.09, requiring significant earnings acceleration to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
